Propranolol disposition in cirrhosis.
作者信息
Jones D B
出版信息
Gut. 1985 Aug;26(8):865. doi: 10.1136/gut.26.8.865.
Abstract
摘要
相似文献
1
Propranolol disposition in cirrhosis.肝硬化患者体内普萘洛尔的处置情况
Gut. 1985 Aug;26(8):865. doi: 10.1136/gut.26.8.865.
2
Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings].
Br J Clin Pharmacol. 1977 Oct;4(5):630P. doi: 10.1111/j.1365-2125.1977.tb00802.x.
3
Pharmacokinetic-hemodynamic interactions in cirrhosis.肝硬化中的药代动力学-血流动力学相互作用。
Semin Liver Dis. 1986 Nov;6(4):299-308. doi: 10.1055/s-2008-1040612.
4
Mechanism for reduced drug clearance in patients with cirrhosis.肝硬化患者药物清除率降低的机制。
Gastroenterology. 1978 Mar;74(3):566-71.
5
6
Intrinsic hepatic clearance in cirrhosis.肝硬化时的肝脏内在清除率。
Gastroenterology. 1978 Aug;75(2):346-8.
7
Propranolol disposition in chronic liver disease: a physiological approach.慢性肝病中普萘洛尔的处置：一种生理学方法。
Clin Pharmacokinet. 1976;1(4):264-79. doi: 10.2165/00003088-197601040-00002.
8
Clearances of propranolol and quinidine.
Am Heart J. 1979 May;97(5):678. doi: 10.1016/0002-8703(79)90200-x.
9
Circadian bioavailability and some effects of propranolol in healthy subjects and in liver cirrhosis.普萘洛尔在健康受试者和肝硬化患者中的昼夜生物利用度及某些效应
Int J Clin Pharmacol Ther Toxicol. 1984 Dec;22(12):653-8.
10
Clearance by the liver in cirrhosis. III. Propranolol uptake by the isolated perfused human liver.
Can J Physiol Pharmacol. 1996 Dec;74(12):1327-32.
引用本文的文献
1
Nanoformulation of Spirooxindole and Methods for Treating Hepatocellular Carcinoma.螺环氧化吲哚的纳米制剂及治疗肝细胞癌的方法。
Pharmaceutics. 2025 Jan 12;17(1):93. doi: 10.3390/pharmaceutics17010093.
本文引用的文献
1
Reduction of liver blood flow and propranolol metabolism by cimetidine.西咪替丁对肝血流量及普萘洛尔代谢的影响
N Engl J Med. 1981 Mar 19;304(12):692-5. doi: 10.1056/NEJM198103193041202.
2
Influence of cimetidine on pharmacokinetics of propranolol.西咪替丁对普萘洛尔药代动力学的影响。
Br Med J (Clin Res Ed). 1981 Jun 13;282(6280):1917-9. doi: 10.1136/bmj.282.6280.1917.
3
4
The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.普萘洛尔的处置。3. 由于人、猴、狗和大鼠体内的血浆结合作用，半衰期和分布容积降低。
J Pharmacol Exp Ther. 1973 Jul;186(1):114-22.
5
Plasma binding and the affinity of propranolol for a beta receptor in man.
Clin Pharmacol Ther. 1976 Aug;20(2):152-7. doi: 10.1002/cpt1976202152.
6
Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.
N Engl J Med. 1978 Dec 28;299(26):1435-9. doi: 10.1056/NEJM197812282992604.
Zotero 插件